About Us

Standard of Care chemotherapeutic agents have significant drawbacks, including debilitating side effects, lack of potency in killing cancer cells, complicated regimens, and multidrug resistance.

Cairn is developing treatments to overcome each of these challenges.

Cairn Therapeutics’ lead candidate, CT-262, was created by Dale Boger, Ph.D. at Scripps Research. Dr. Boger is considered the premier researcher of duocarmycin drugs.

  • Richard and Alice Cramer Professor of Chemistry at Skaggs Institute for Chemical Biology, Scripps Research
  • Ph.D., Chemistry from Harvard University (1980)
  • Elected Member of National Academy of Sciences (2014)

 

Discover Our Work
Dr. Dale Boger

Meet Our Leadership Team

Our leadership team’s experience spans hundreds of drugs developed and dozens of products launched.

W. Scott Evangelista

W. Scott Evangelista

CEO

Learn More

W. Scott Evangelista
CEO

  • Former President and COO of startup biopharmaceutical company Ironshore Pharmaceuticals
  • Previously President of Integrated Healthcare Services at IQVIA (formerly Quintiles)
  • Maintains relationships with key leadership at most of the Top Biopharmaceutical companies
Q
Tom Fritz

Tom Fritz

COO

Learn More

Tom Fritz
COO

  • More than 30 years experience in drug development and regulatory consulting, helping mostly startup companies bring their drugs to market, directing areas such as nonclinical, clinical, and CMC programs
  • Involved in over 100 INDs/CTAs and dozens of drug approvals over the years
  • Previously Founder & COO of ImaRx Pharmaceutical Corp, bringing company to full-scale operation with 3 drug products approved or in final FDA approval stages
  • Doctoral work completed at Arizona Cancer Center
Q
Sutton Faller, MS, MBA

Sutton Faller, MS, MBA

CAO

Learn More

Sutton Faller, MS, MBA
CAO

  • Broad operational experience across numerous life sciences companies and management consultancies
  • Previously head of strategy at Ironshore Pharmaceuticals and Commercial division at IQVIA
  • Master’s degree in neuroscience from Yale University
Q

Meet Our Experts

Scientific and Medical Advisors

Our Scientific/Medical team is led by world-renowned experts in medicinal chemistry and cutting-edge treatment of oncology.

Learn More
Dale Boger, Ph.D.
Creator of CT-262

Dale Boger, Ph.D.
Inventor

  • Richard & Alice Cramer Professor of Chemistry at Skaggs Institute for Chemical Biology, Scripps Research
  • Elected Member of National Academy of Sciences
  • Paul Janssen Prize for Creativity in Organic Synthesis
  • Ph.D., Chemistry from Harvard University
Q
Manmeet Ahluwalia, MD
Medical Advisor

Manmeet Ahluwalia, MD
Medical Advisor

  • Chief of Solid Tumor Medical Oncology, Chief Scientific Officer & Deputy Director, Miami Cancer Institute
  • Previously program director Neuro-Oncology fellowship at Cleveland Clinic
  • Professor of Translational Medicine, Herbert Wertheim College of Medicine, Florida Int’l University
Q
Roger Rajewski, Ph.D.
Scientific Advisor

Roger Rajewski, Ph.D.
Scientific Advisor

  • Research Professor, Department of Pharmaceutical Chemistry, University of Kansas
  • Previously Research Professor of Biotechnology Innovation & Optimization Center, University of Kansas
Q

Board of Directors

Our Board of Directors draws on significant pharmaceutical executive experience.

Learn More
Roger Newton, Ph.D.
Chairman of the Board

Roger Newton, Ph.D.
Chairman of the Board

  • Co-discoverer and product champion of Lipitor
  • Founded numerous pharma companies including Esperion Therapeutics which sold to Pfizer for $1.3B
  • Serves on boards of Celsee, Rubicon Genomics, and Swift BioSciences
Q
Wes Wheeler
Board Member

Wes Wheeler
Board Member

  • Recently retired as President of UPS’s $10B Healthcare division
  • Formerly CEO of DSM and Patheon (now ThermoFisher), Valeant, and Marken LLP
  • Serves on boards of BioTouch and Envirotainer
Q
W. Scott Evangelista
Board Member

W. Scott Evangelista
Board Member

  • Serves on board of Worldwide Clinical Trials
Q